Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model

Transplantation
M J HanawayS J Knechtle

Abstract

B7.75-84, a 10-amino-acid peptide derived from the HLA-B7 molecule, prolongs rat heterotopic cardiac allograft survival time (GST) when used with cyclosporine in the Lewis-to-ACI strain combination. We evaluated the ability of B7.75-84 to prolong GST in other strain combinations without cyclosporine and studied the effect of B7.75-84 on the immune response in the Wistar-Furth (WF)-to-ACI strain combination. GST was markedly prolonged in most low-responder (ACI) recipients but only slightly prolonged in the high-responder (Lewis) recipient. Cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) limiting dilution assays (LDA) were performed 10 days after cardiac allografts from WF donors were placed in ACI recipients treated with B7.75-84. HTL-LDA assays at 10 days posttransplant showed a slight decrease in HTL precursor frequency and a decrease in their IL-2 production in B7.75-84 treated recipients with prolonged GST in response to donor antigen as well as third-party (Lewis) antigen. CTL-LDA assays at day 10 showed no difference in CTL precursor frequency among treated recipients but did show a significant decrease in CTL killing activity against donor cells in recipients with prolonged GST. No significant difference in CT...Continue Reading

References

Dec 21, 1989·The New England Journal of Medicine·B D Kahan
May 1, 1995·Clinical Immunology and Immunopathology·A M Krensky, C Clayberger

❮ Previous
Next ❯

Citations

Sep 2, 1998·Transplantation Proceedings·C C Magee, M H Sayegh
Nov 22, 1997·Current Opinion in Immunology·C C Magee, M H Sayegh
Nov 5, 1997·The Journal of Surgical Research·D G TiceE C Squiers
Mar 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yun JiangCarol Clayberger
Sep 7, 1999·Journal of the American Society of Nephrology : JASN·C C MageeM Sayegh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.